Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for IEC-HS After CAR-T Therapy (RISE)
NCT07424222Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis (IEC-HS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Participants with Clinical Response at 8 weeks and Number of Adverse events at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis (IEC-HS)
Beyond the preview
Go deeper on NCT07424222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424222.